SCHEMBL6202230

SCHEMBL6202230

O=C(O)c1cnc2ccc(Cl)cc2c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
HPGD P15428 2/20 0.50
HSD17B10 Q99714 2/20 0.50
PTGES O14684 1/20 0.50
ALOX5 P09917 1/20 0.50
CYP2C9 P11712 1/20 0.50
CASP7 P55210 1/20 0.50
HIF1A Q16665 1/20 0.50
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
LMNA P02545 1/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
KDM4E B2RXH2 2/20 0.46
MAPT P10636 2/20 0.46
PKM P14618 1/20 0.46
HTT P42858 1/20 0.46
DHODH Q02127 4/20 0.46
F7 P08709 1/20 0.45
F3 P13726 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1610495 0.87 CYP1A2 (0.49) ALDH1A1HPGDHSD17B10PTGESALOX5
SCHEMBL30592903 0.87 CYP1A2 (0.49) ALDH1A1HPGDHSD17B10PTGESALOX5
Hydrochloric Acid SCHEMBL11866946 0.86 CYP1A2 (0.48) ALDH1A1HPGDHSD17B10PTGESALOX5
SCHEMBL5756614 0.86 SRD5A2 (0.46) ALDH1A1HPGDHSD17B10MEN1KMT2A
SCHEMBL2721434 0.85 LMNA (0.58) ALDH1A1HPGDHSD17B10PTGESALOX5
Hydrochloric Acid SCHEMBL9872122 0.84 LMNA (0.60) ALDH1A1HPGDHSD17B10PTGESALOX5
SCHEMBL9875561 0.84 MEN1 (0.61) ALDH1A1HPGDLMNAMEN1KMT2A
SCHEMBL9874420 0.83 MEN1 (0.51) ALDH1A1CYP2C9LMNAMEN1KMT2A
SCHEMBL440411 0.83 HAVCR2 (0.52) ALDH1A1HPGDHSD17B10PTGESALOX5
SCHEMBL12786944 0.81 ALDH1A1 (0.49) ALDH1A1HPGDHSD17B10CYP2C9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12486234-B2 PAPD5 inhibitors and methods of use thereof CHILDREN'S MEDICAL CENTER CORPORATION (US) 2025-12-02 US disclosed
CN-119798159-A PAPD5 inhibitors and methods of use thereof 儿童医学中心公司 2025-04-11 CN disclosed
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-01-23 US disclosed
EP-4423081-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF The Children's Medical Center Corporation (US) 2024-09-04 EP disclosed
CN-118201920-A PAPD5 inhibitors and methods of use thereof 儿童医疗中心公司 2024-06-14 CN disclosed
WO-2023086220-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-05-19 WO disclosed
WO-2023086220-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-05-19 WO disclosed
US-20220274928-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION 2022-09-01 US disclosed
EP-3959197-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF CHILDREN'S MEDICAL CENTER CORPORATION (US) 2022-03-02 EP disclosed
CN-113993848-A Inhibitors of PAPD5 and methods of use thereof 儿童医学中心公司 2022-01-28 CN disclosed
CN-1128790-C 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents UPJOHN CO (US) 2003-11-26 CN disclosed
CN-1281439-A 4-hydroxyquinoline-3-carboxamide and hydrazide compounds as antiviral agents UPJOHN CO (US) 2001-01-24 CN disclosed
EP-1042295-A1 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2000-10-11 EP disclosed
US-6093732-A PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION PHARMACIA & UPJOHN COMPANY (US) 2000-07-25 US disclosed
WO-1999032450-A1 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 1999-07-01 WO disclosed
CN-85106626-A The preparation of 4-amino-2-phenyl-quinoline 1987-03-25 CN disclosed
US-4588731-A Derivatives of isoxazolo[4,5-c]quinoline(2H)-3-one and method of preparation and use as anxiolytic agents ROUSSEL UCLAF (FR) 1986-05-13 US disclosed
EP-0070767-B1 QUINOLINE DERIVATIVES, THEIR SALTS, THEIR PREPARATION, THEIR USE AS MEDICINES AND COMPOSITIONS CONTAINING THEM ROUSSEL-UCLAF (FR) 1985-04-10 EP disclosed
EP-0070767-A1 Quinoline derivatives, their salts, their preparation, their use as medicines and compositions containing them ROUSSEL-UCLAF (FR) 1983-01-26 EP disclosed
US-4202985-A ANTIFUNGAL AND ANTIBACTERIAL AGENTS E. R. SQUIBB & SONS, INC. (US) 1980-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274928-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF POT1, PARP15, TERT ALDH1A1 2425/4885HPGD 769/4885HSD17B10 1532/4885
US-12486234-B2 PAPD5 inhibitors and methods of use thereof POT1, PARP15, TERT ALDH1A1 2425/4885HPGD 769/4885HSD17B10 1532/4885
US-20250026769-A1 PAPD5 INHIBITORS AND METHODS OF USE THEREOF POT1, PARP15, TERT ALDH1A1 2733/4885HPGD 1029/4885HSD17B10 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.